Navigation Links
Pasteuria Bioscience Taps New CEO David N. Duncan
Date:10/30/2007

ALACHUA, Fla., Oct. 30 /PRNewswire/ -- Pasteuria Bioscience, Inc. (http://www.pasteuriabio.com), a Florida biotech company developing biological control products for agriculture's largest unmet pest problem, announced today that David N. Duncan, Ph.D., has been named as the new Chief Executive Officer. Dr. Duncan has also been elected to the Company's board of directors. He succeeds Dr. Kelly Smith who will remain active with the Company as its Chief Technology Officer.

Following his formal education at Indiana State and Michigan State universities, Dr. Duncan joined Monsanto Company where he held positions in product development, marketing, government and regulatory affairs; and as both a commercial development and business unit executive. Notably, Duncan led Monsanto's turf and ornamental business and the development of Dimension(R) turf herbicide. Dimension is today one of the premier products used by turfgrass professionals and homeowners.

After retirement from Monsanto, Duncan took on the CEO role at Chlorogen, Inc. where he raised $10M from a syndicate of venture investors and proceeded to build the company into a highly regarded start-up focused on human therapeutic protein expression and production in tobacco. "I have been involved with groundbreaking technologies and trend-setting companies my entire career. Pasteuria, with its focus on a revolutionary approach to nematode control, offers the same kind of challenge and exciting opportunity to make a difference," said Duncan. "Along with our dedicated science team and the support of committed investors, I am convinced we have the talent and resources to take this technology through scale-up manufacturing, regulatory approval and a successful commercial launch. The global agriculture industry needs this technology-based solution and we intend to bring it to them."

Recent investor LSP through its BioVentures fund is also pleased to have Duncan on board at Pasteuria. "Dave's combination of past experience in product development and as a CEO for a start-up company will help Pasteuria greatly as they transition from a research to a development and production company," said Jorg Riesmeier, Partner at LSP BioVentures and Pasteuria board member.

Plant-parasitic nematodes are agriculture's largest unmet pest problem. These microscopic worms attack plant roots, causing an estimated $100 billion in worldwide crop damage annually. Pasteuria has developed a patented, cost- effective commercial scale process for the production of Pasteuria bacteria, a naturally occurring predator. These predatory microbes specifically target, infect, and kill selected nematodes-without leaving toxic crop residues. Other organisms remain unharmed, soil and water is left free of contaminants, and there are no known human exposure risks. Additionally, Pasteuria's microbes are highly durable and require no special handling or storage conditions. The company is on pace to file a submission for registration to EPA by mid-2008.

Pasteuria's investment partners include LSP BioVentures (http://www.lspvc.com), a $100 million fund focused on early to mid-staged companies in the areas of agriculture, food and nutrition, health & wellness, biofuels and related platform technologies; Advantage Capital (http://www.advantagecap.com), a venture capital and private equity firm focused on early-stage companies and other investments supporting state and local economic development; and Gordon River Capital (http://www.gulfshorecap.com), an affiliate of Florida Gulfshore Capital, a Naples, FL based private investment firm involved in the development and sale of consumer, industrial, and medical products and services.

Pasteuria Bioscience, founded in 2003, is located at the University of Florida's Sid Martin Biotechnology Incubator in Alachua, Florida, a nationally recognized bio-business development program providing facilities, equipment, and introductions to capital and business leadership in an entrepreneurial environment.


'/>"/>
SOURCE Pasteuria Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ... with artificial intelligence, real-time decision support tools in the emergency ... at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology ... the David Intercontinental Hotel in Tel Aviv, Israel ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2016. The cash dividend ... July 29, 2016 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:5/22/2016)... (PRWEB) , ... May 22, 2016 , ... Doctors in ... in combating the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article ... in the University of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/21/2016)... , March 22, 2016 ... recognition with passcodes for superior security   ... a leading provider of secure digital communications services, today ... biometric technology and offer enterprise customers, particularly those in ... facial recognition and voice authentication within a mobile app, ...
Breaking Biology News(10 mins):